

**DISCLOSURE OF INFORMATION TO THE SHAREHOLDERS OF
PT SARANA MEDITAMA METROPOLITAN TBK ("COMPANY")
IN ACCORDANCE WITH THE PROPOSED CAPITAL INCREASE WITHOUT PRE-EMPTIVE RIGHTS
("PMTHMETD") FOR THE IMPLEMENTATION OF MANAGEMENT AND EMPLOYEES SHARES
OWNERSHIP PROGRAM ("MESOP PROGRAM")**

This Disclosure of Information is submitted in order to comply with Financial Services Authority Regulation Number 14/POJK.04/2019 concerning Amendment to Financial Services Authority Regulation Number 32/POJK.04/2015 concerning Capital Increases in Public Companies With Pre-Emptive Rights ("POJK No. 14/2019").



We Care with Passion

PT SARANA MEDITAMA METROPOLITAN Tbk
Domiciled in East Jakarta

Business activities:

Human Health Activities by carrying out Main Business Activities (Private Hospital Activities, Practice Activities of General Practitioner, Specialist Doctors, and Dentists, as well as Medical Evacuation Activities) and other activities to support the Main Business Activities.

Headquarters:

Jl. Pulomas Barat VI No. 20, Kayu Putih, Pulo Gadung,
East Jakarta 13210, Indonesia.

Ph. (021) 2977 9977

Fax. (021) 2977 9977

Website: www.emc.id

Email: corsec@emc.id

This information is announced on the Company's website and Indonesia Stock Exchange ("IDX") website in connection with the Company's plan to implement the MESOP Program through PMTHMETD ("**Proposed Transaction**"), which requires approval from the shareholders that to be requested through the Extraordinary General Meeting of Shareholders which will be held on Wednesday, 14 December 2022, in which the EGMS Announcement has been made through the Company's website, IDX website, and KSEI website, along on the date of this Disclosure of Information.

The Board of Directors and Board of Commissioners of the Company hereby declare that they are fully responsible for the accuracy of the information contained in this Disclosure of Information that was drafted after exercising a reasonable examination, and also confirm that the material information related to the Proposed Transaction contained in this Disclosure of Information is true and there are no other material facts that are not disclosed or omitted which may result in the information in this Disclosure of Information being untrue and/or misleading.

This Disclosure of Information is published on 7 November 2022.

DEFINITION

“The Company’s AoA”	:	The latest amendment and restatement to the Company’s articles of association based on Deed No. 5 dated 8 June 2022, drawn up before Aryanti Artisari, S.H., Notary in South Jakarta, which has obtained the approval of the MOLHR through Decree No. AHU-0047073.AH.01.02.TAHUN 2022 dated 8 July 2022, and has been notified to and received by the MOLHR through (i) Letter of Acceptance of Notification of Amendment to Articles of Association No. AHU-AH.01.03-0262325 dated 8 July 2022 and (ii) Letter of Acceptance of Notification of Changes in Company Data No. AHU-AH.01.09-0030675 dated 8 July 2022, all three of which have been registered in Company Register No. AHU-0130200.AH.01.11.TAHUN 2022 dated 8 July 2022.
“BAE”	:	Security Administration Bureau, in which party that carries out the administration of the Company’s shares appointed by the Company, PT Bima Registra, with domicile in Jakarta.
“IDX”	:	Stands for Indonesia Stock Exchange, a Limited Liability Company incorporated under the laws of the Republic of Indonesia as well as domicile in Jakarta, and which this Company’s shares are listed at.
“Shareholder Register”	:	A list containing the names of the shareholders in the Company as stipulated under the Company Law.
“Trading Days”	:	The day when IDX or the substituting legal body organize stock exchange activities pursuant to the applicable laws and regulations and other provisions applied by stock exchange in question and when the banks process the clearance.
“Calendar Days”	:	Any day in 1 (one) year according to Gregorian calendar system without any exception, including Sundays and national holidays as decided at any time by the Government of Republic of Indonesia and normal working days, which due to certain conditions have been set by the Government of Indonesia as not normal working days.
“Working Days”	:	The days of Monday through Friday, except national holidays or other holidays as decided by the Government of Republic of Indonesia.
“KSEI”	:	Stands for PT Kustodian Sentral Efek Indonesia, having domicile in Jakarta in the capacity of Securities Depository and Settlement Institute as stipulated under UUPM.
“MOLHR”	:	Stands for The Ministry of Law and Human Rights.
“Financial Services Authority” or “OJK”	:	An independent institute as referred to in Law No. 21 of 2011 concerning Financial Services Authority (“ OJK Law ”) with duties and responsibilities inclusive of regulating and overseeing financial service activities in banking sector, capital market, insurance, pension fund, financing institutes and other finance institutes, which as from 31 December 2012, OJK has been assigned as institute to replace and as such receive the rights and obligations necessary to perform the regulatory and supervisory functions of Bapepam and/or Bapepam and LK pursuant to provisions of Article 55 of OJK Law.

- “Controlled Companies”** : Any company that are controlled either directly or indirectly by the Company.
- “Shareholders”** : The parties that shall reserve the right to reap benefits from Company’s shares kept and administered in security accounts of KSEI, registered in Company’s Shareholder Register administered by Security Administration Bureau namely PT Bima Registra.
- “Independent Shareholders”** : Shareholders who do not have a personal economic interest in relation to the PMTHMETD, and:
- a. they are not a member of the Board of Directors, member of the Board of Commissioners, major shareholder, and controlling the shareholder of the Company; or
 - b. they are not an affiliate of the members of the Board of Directors, members of the Board of Commissioners, major shareholders, and the controlling shareholder of the Company.
- “Rule No. I-A”** : Decision of the IDX Board of Directors Number: Kep-00101/BEI/12-2021 dated 21 December 2021 concerning Amendment to Regulation Number I-A concerning the Listing of Shares and Equity Securities Other than Shares Issued by the Listed Company which replaces the Decree of the IDX Board of Directors Number: Kep-00183/BEI/12-2018 dated 26 December 2018 and its attachments.
- “MESOP Program Participants”** : All employees, members of the Board of Directors, and members of the Board of Commissioners who meet the following requirements:
- a. members of the Board of Commissioners of the Company (except for the Independent Commissioners) and Controlled Companies approved by the Nomination and Remuneration Committee of the Company who served at the date of free shares distribution as part of the compensation;
 - b. members of the Board of Directors of the Company and Controlled Companies who are proposed by the Board of Directors and approved by the Nomination and Remuneration Committee of the Company who served at the date of free shares distribution as part of the compensation; and
 - c. permanent employees of the Company and Controlled Companies appointed by the Board of Directors of the Company with the following requirements: (i) have a position with a minimum rank of Grade N-3 and above; (ii) recorded in the employees data of the Company and the Controlled Companies; and (iii) have worked for at least 6 (six) months prior to the date of free shares distribution as part of compensation.
- “POJK No. 15/2020”** : OJK Regulation No. 15/POJK.04/2020 dated 21 April 2020 concerning the Plan and Implementation of General Meeting of Shareholders of Public Companies.
- “POJK No. 14/2019”** : OJK Regulation No. 14/POJK.04/2019 dated 30 April 2019 concerning Amendment to the Financial Services Authority Regulation No. 32/POJK.04/2015 concerning Capital Increases in Public Companies With Pre-Emptive Rights.

- “EGMS”** : Extraordinary General Meeting of Shareholders of the Company to be convened on Wednesday, 14 December 2022.
- “Shares”** : All shares that have been issued and fully paid in the Company on the date of this Disclosure of Information is published.
- “New Shares”** : A maximum of 35,000,000 (thirty five million) new shares to be issued from the Company’s portfolio with a nominal value of Rp20,- per share or a maximum of 0.2% (zero point two percent) of the issued and paid-up capital in the Company, amounting to 17,129,632,545 (seventeen billion one hundred twenty nine million six hundred thirty two thousand five hundred forty five) shares based on The Company's AoA for the implementation of the Proposed Transaction by the Company.
- “UUPM”** : Law No. 8 of 1995 dated 10 November 1995 concerning the Capital Market, based on the State Gazette of the Republic of Indonesia No. 64 of 1995, Supplement No. 3608.
- “Company Law”** : Law No. 40 of 2007 dated 16 August 2007 concerning Limited Liability Companies, based on the State Gazette of the Republic of Indonesia No. 106 of 2007, Supplement No. 4746.

I. THE PURPOSE AND OBJECTIVES OF MESOP PROGRAM

In the recent years, the Company has achieved better performance and growth that strengthen the Company's capital structure. The Company believes that such improvement can occur because of the commitment and hard work of the management and employees. Therefore, as a form of appreciation and effort from the Company to continually optimize performance and maintain sustainable growth for the Company, the Company plans to implement the Management and Employee Stock Ownership Program ("**MESOP Program**"). In addition, MESOP Program also aims to increase sense of belonging for each of the management member and employee of the Company and Controlled Companies ("**Company Group**"), both towards to the Company and the Company Group. Through MESOP Program, the Company hopes that the work performance of MESOP Program Participants can be improved so that in the end, the Company Group's performance can also be improved.

By referring to the provisions of POJK No. 14/2019, the Company plans to conduct PMTHMETD in order to implement the MESOP Program by issuing a maximum of 35,000,000 (thirty five million) new shares from the Company's portfolio or equivalent to 0.2% (zero point two percent) of the total issued and paid-up capital in the Company, in which the new shares ate to be issued to the MESOP Program Participants with free shares ("**New Shares**").

Based on the Company's Articles of Association which have been amended several times as last amended and restated in the Deed No. 5 dated 8 June 2022, drawn up before Aryanti Artisari, S.H., Notary in South Jakarta, which has obtained the approval of the MOLHR through Decree No. AHU-0047073.AH.01.02.TAHUN 2022 dated 8 July 2022, and has been notified to and received by the MOLHR through (i) Letter of Acceptance of Notification of Amendment to Articles of Association No. AHU-AH.01.03-0262325 dated 8 July 2022 and (ii) Letter of Acceptance of Notification of Changes in Company Data No. AHU-AH.01.09-0030675 dated 8 July 2022, all three of which have been registered in Company Register No. AHU-0130200.AH.01.11.TAHUN 2022 dated 8 July 2022, the number of the Company's issued and paid-up capital is 17,129,632,545 (seventeen billion one hundred twenty nine million six hundred thirty two thousand five hundred forty five) shares or representing 68.52% (sixty eight point five two percent) of the total authorized capital of the Company.

This Proposed Transaction requires prior approval from the Company's Independent Shareholders which will be requested through the Company's EGMS that will be held on Wednesday, 14 December 2022 at Studio SCTV, SCTV Tower 8th Floor, Senayan City, Jl. Asia Afrika Lot 19, Central Jakarta, 10270, Indonesia.

Apart from what has been disclosed in this Disclosure of Information, there are no other regulatory provisions that must be met apart from the OJK Regulation and IDX Rule, and there is no approval from the government, agency, or other institution that the Company needs to obtain in connection with the implementation of the Proposed Transaction.

As of the date of this Disclosure of Information, the Company is not involved in any material cases or disputes, either in court or out of the court, which may negatively affect the business continuity of the Company and/or its Controlled Companies and the implementation of the Proposed Transaction.

Until now, the Company still has a PMTHMETD program for the purpose of other than improving financial position by issuing a maximum of 1,712,963,255 (one billion seven hundred twelve million nine hundred sixty three thousand two hundred fifty five) shares of the Company or equivalent to 10% (ten percent) of the total issued and paid-up capital in the Company, which were approved at the Company's EGMS on 26 October 2021 as stated in the Deed of Minutes of the EGMS No. 73 dated 26 October 2021, where the Company's PMTHMETD program has not been implemented by the Company and is still valid for 2 (two) years from 26 October 2021.

II. COMPANY OVERVIEW

A. Company Background

The Company was established under the name PT Sarana Meditama Metropolitan and was initially engaged in the business of engineering work, general trading, services, industry and crafts, agency, and investment in buildings. The establishment is stated in the Deed No. 27 dated 13 November 1984, drawn up before Budiarti Karnadi S.H., Notary in Jakarta, which has been approved by the Minister of Justice of the Republic of Indonesia through Decree No. C2-933.HT.01.01.TH.85 dated 25 February 1985 ("**Deed of Establishment**"). The Company then listed its shares on the IDX or conducted go-public on 11 January 2013. By referring to the provisions of the Company Law and other laws and regulations in the capital market sector, the name PT Sarana Meditama Metropolitan was changed to PT Sarana Meditama Metropolitan Tbk as a result of being listed publicly.

The Company is domiciled in East Jakarta with its headquarters located at Jalan Pulomas Barat VI No. 20, RT 009/RW 06, Kayu Putih Village, Pulo Gadung District, East Jakarta Administrative City, Special Capital Region of Jakarta.

The shareholders of the Company have approved changes to the entire articles of association, among others, to be adjusted to POJK No. 15/2020 which is based on Deed No. 33 dated 10 May 2021, drawn up before Aulia Taufani, S.H., Notary in South Jakarta, which has been notified to and accepted by the Menkumham through the Letter of Acceptance of Notification of Amendment to the Articles of Association No. AHU-AH.01.03-0304276 dated 11 May 2021.

In addition, the articles of association of the Company have been amended several times as last amended and restated in the Deed No. 5 dated 8 June 2022, drawn up before Aryanti Artisari, S.H., Notary in South Jakarta, which has obtained the approval of the MOLHR through Decree No. AHU-0047073.AH.01.02.TAHUN 2022 dated 8 July 2022, and has been notified to and received by the MOLHR through (i) Letter of Acceptance of Notification of Amendment to Articles of Association No. AHU-AH.01.03-0262325 dated 8 July 2022 and (ii) Letter of Acceptance of Notification of Changes in Company Data No. AHU-AH.01.09-0030675 dated 8 July 2022, all three of which have been registered in Company Register No. AHU-0130200.AH.01.11.TAHUN 2022 dated 8 July 2022 ("**The Company's AoA**").

B. Business Activities

Based on Article 3 of the Company's AoA, the Company's current purposes and objectives are to do business in the field of human health activities, by carrying out business activities:

- a. Main Business Activities, in the form of:
 - (i) Private Hospital Activities;
 - (ii) General Practitioner Practice Activities;
 - (iii) Specialist Practice Activities;
 - (iv) Dentist Practice Activities; and
 - (v) Medical Evacuation.
- b. Other business activities that support the Main Business Activities, which include:
 - (i) activities related to dental and oral health such as prosthetic equipment and activities related to health workers such as services of midwives, nurses, and physiotherapy;
 - (ii) development of the Company's facilities and infrastructure;
 - (iii) laboratory testing activities; and
 - (iv) health services, education, and training to support government programs in the health sector.

C. Capital Structure and Shares Ownership

Based on the Company's Shareholders Register which compiled by PT Bima Registra, acting as the Company's BAE, the structure of the Company's shares ownership as of 31 October 2022 is as below:

Description	Nominal Value per Share		
	Shares	Nominal Value (Rp)	%
Authorized Capital	25,000,000,000	500,000,000,000	-
Issued and Paid-Up Capital			
The Shareholders:			
1. PT Elang Mahkota Teknologi Tbk	13,079,382,045	261,587,640,900	76.36
2. The Public	4,050,250,500	81,005,010,000	23.64
Total Issued and Paid Up Capital	17,129,632,545	342,592,650,900	100
Total Portfolio Shares	7,870,367,455	157,407,349,100	-

D. Management and Supervision

Based on the Deed of the General Meeting of Shareholders Resolutions No. 4 dated 8 June 2022, drawn up before Aryanti Artisari, S.H., Notary in South Jakarta, which has been notified to and received by the MOLHR through Letter of Acceptance of Notification of Changes in Company Data No. AHU-AH.01.09-0025649 dated 24 June 2022 ("**Deed No. 4/2022**"), the composition of the Board of Directors and Board of Commissioners of the Company are as follows:

Board of Commissioners

President Commissioner and Independent Commissioner	:	Robert Pakpahan
Independent Commissioner	:	Unggung Cahyono

Board of Directors

President Director	:	Jusup Halimi
Vice President Director	:	Juniwati Gunawan
Director	:	Meta Dewi Thedja
Director	:	drg. Nailufar, MARS
Director	:	Kusmiati
Director	:	Armen Antonius Djan

As of the date of this Disclosure of Information, the Company's Board of Directors and Board of Commissioners are not involved in any material cases or disputes, either in court or out of the court, which may negatively affect the business continuity of the Company and/or Controlled Companies and the implementation of the Proposed Transaction.

III. INFORMATION REGARDING MESOP PROGRAM

The MESOP Program referred to in this Proposed Transaction is a program of offering the Company's newly free shares to employees, members of the Board of Directors, and members of the Board of Commissioners of the Company and/or Controlled Companies who meet the requirements to own the Company's shares by way of the issuance of New Shares by the Company with a maximum of 35,000,000 (thirty five million) shares with a nominal value per share of Rp20 (twenty Rupiah), in which the exercise price will be determined by the Company's Board of Directors with the approval of the Company's Board of Commissioners in accordance with the provisions of Point V.2 Attachment II of Rule No. I-A.

A. MESOP Program Participants

In this Proposed Transaction, MESOP Program Participants are all employees, members of the Board of Directors, and members of the Board of Commissioners who meet the following requirements:

1. members of the Board of Commissioners of the Company (except for the Independent Commissioners) and Controlled Companies approved by the Nomination and Remuneration Committee of the Company who served at the date of free shares distribution as part of the compensation;
2. members of the Board of Directors of the Company and Controlled Companies who are proposed by the Board of Directors and approved by the Nomination and Remuneration Committee of the Company who served at the date of free shares distribution as part of the compensation; and
3. permanent employees of the Company and Controlled Companies appointed by the Board of Directors of the Company with the following requirements: (i) have a position with a minimum rank of Grade N-3 and above; (ii) recorded in the employees data of the Company and the Controlled Companies; and (iii) have worked for at least 6 (six) months prior to the date of free shares distribution as part of compensation;

hereinafter referred to as "MESOP Program Participants".

B. Shares Distribution Period

By referring to the provisions of POJK No. 14/2019, the MESOP Program will be implemented within a period of 5 (five) years from the date of the GMS which approved the MESOP Program. In this case, if approved in the Company's EGMS which will be held on 14 December 2022, then the implementation period of the MESOP Program is from 2022 to 2027.

If deemed relevant to the Company's Board of Directors, in which there must be a prior approval from the Company's Nomination and Remuneration Committee, each share of the Company distributed to MESOP Program Participants will have a vesting period of 4 (four) years, in which the rights to the Company's shares will be issued for 25 % (twenty five percent) of the full rights annually for 4 (four) consecutive years. The Company's shares dividend that will be distributed to MESOP Program Participants are only the dividend from shares that have been issued, in which will be officially distributed to MESOP Program Participants.

The New Shares will be distributed to MESOP Program Participants in several stages to be determined by the Company's Board of Directors with prior approval from the Company's Nomination and Remuneration Committee. The Company's Nomination and Remuneration Committee will calculate the shares to be allocated to eligible MESOP Program Participants based on the participants' work performance and by taking into account their duties and responsibilities in making decisions that have a significant impact on the Company's performance.

C. Determination of the Exercise Price of New Shares

The determination of the exercise price of New Shares in the MESOP Program will be carried out by the Board of Directors with a prior approval from the Company's Board of Commissioners with due observance of the applicable legal provisions, including the Company Law, laws and regulations in

the capital market, and accounting standards. In reference to the provisions of Point V.2 Attachment II of Rule No. I-A, the exercise price of the New Shares shall be set at least 90% (ninety percent) of the average closing price of the Company's shares for a period of 25 (twenty five) consecutive Trading Days in the regular market before the listing application is made or on the date of submission of notification of the Proposed Transaction to the IDX.

The source of funding that will be used by the Company to implement this Proposed Transaction comes from internal cash and/or other sources which will be determined further by the Company.

When implementing this Proposed Transaction, the Company is committed to comply with the provisions of the applicable laws and regulations, including to fulfill and/or comply with all forms of tax obligations arising from the implementation of the MESOP Program.

D. MESOP Program Shares Status

The New Shares in the MESOP Program have the same rights, position, and degrees in all respects as other shares that have been issued and fully paid into the Company, including in terms of acquiring rights to dividends and issuing voting rights at the GMS and other corporate actions to be implemented by the Company.

The New Shares are the shares that have just been issued from the Company's portfolio and in this case will be listed on the IDX in accordance with the applicable laws and regulations.

E. MESOP Program Shares Issuance and Implementation Period

The issuance and implementation period of the MESOP Program will be determined further by taking into account the provisions of the prevailing laws and regulations in the capital market sector.

F. MESOP Program Requirements

By taking into account the applicable laws and regulations, this MESOP Program can be carried out by first fulfilling the following requirements:

1. The Company has obtained an approval from the General Meeting of Shareholders to implement the MESOP Program;
2. The Company has obtained IDX approval for the pre-listing application of the additional shares originating from the MESOP Program;
3. If any of the MESOP Program Participants resigns from his/her position at the Company or Controlled Companies, all shares to be granted but have not met the vesting period will be forfeited and the said MESOP Program Participant is not entitled to such shares. If any of the MESOP Program Participants is dismissed from his/her position at the Company or Controlled Companies, all shares to be granted but have not met the vesting period will be forfeited and the said MESOP Program Participant is not entitled to such shares; and
4. Other requirements which will be further determined by the Board of Directors after receiving a recommendation from the Company's Nomination and Remuneration Committee.

G. The Company's Capital Pro Forma and Shareholders Structure in Relation to the MESOP Program Implementation

With reference to the Company's Shareholders Register as of 31 October 2022 from PT Bima Registra, the following is the pro forma of the Company's capital and shareholder composition before and after the issuance of New Shares:

DESCRIPTION	Before Issuance of MESOP Program Shares			After Issuance of MESOP Program Shares		
	Nominal Value per Share Rp20			Nominal Value per Share Rp20		
	Shares	Nominal Value (Rp)	%	Shares	Nominal Value (Rp)	%
Authorized Capital	25,000,000,000	500,000,000,000	-	25,000,000,000	500,000,000,000	-
Issued and Paid-Up Capital						
The Shareholders:						
1 PT Elang Mahkota Teknologi Tbk*	13,079,382,045	261,587,640,900	76.36	13,079,382,045	261,587,640,900	76.20
2 The Public	4,050,250,500	81,005,010,000	23.64	4,050,250,500	81,005,010,000	23.60
3 MESOP Program	-	-	-	35,000,000	700,000,000	0.20
Total Issued and Paid-Up Capital	17,129,632,545	342,592,650,900	100	17,164,632,545	343,292,650,900	100
Total Portfolio Shares	7,870,367,455	157,407,349,100	-	7,835,367,455	156,707,349,100	-

*Controlling Shareholder

By referring to the pro forma table of capital and shareholders composition of the Company above, the issuance of all New Shares for the MESOP Program implementation will cause the current shareholders of the Company to experience a dilution of shares ownership of a maximum of 0.2% (zero point two percent).

The number of shares of the Company owned by members of the Board of Commissioners and Board of Directors of the Company based on the Register of Shareholders of the Company as of 31 October 2022 are as follows:

No	Name	Title	Shares	Percentage (%)
1	Robert Pakpahan	President Commissioner and Independent Commissioner	0	-
2	Unggung Cahyono	Independent Commissioner	0	-
3	Jusup Halimi	President Director	0	-
4	Juniwati Gunawan	Vice President Director	0	-
5	Meta Dewi Thedja	Director	0	-
6	drg. Nailufar, MARS	Director	0	-
7	Kusmiati	Director	0	-
8	Armen Antonius Djan	Director	0	-

On the date of this Disclosure of Information, the Ultimate Beneficiary Owner of the Company is Eddy Kusnadi Sariaatmadja.

The Company has never taken a corporate action in the form of buying back the Company's shares so that at the time this Disclosure of Information is published, the Company does not have treasury stock.

IV. THE STATEMENT OF BOARD OF DIRECTORS AND BOARD OF COMMISSIONERS

The information described in this Disclosure of Information has been approved by the Board of Commissioners and the Board of Directors of the Company, who are responsible for the validity of all information disclosed. The Board of Commissioners and Board of Directors of the Company hereby declare that all material information and opinions expressed in this Disclosure of Information are true and can be accounted for and there is no other information that has not been disclosed which may lead to incorrect or misleading information. The Board of Commissioners and Board of Directors of the Company have reviewed the Proposed Transaction, including assessing the risks and benefits for the Company and all shareholders. Therefore, based on trust and confidence that the Proposed Transaction is the best choice to achieve benefits for the Company, the Board of Directors and Board of Commissioners of the Company recommend to shareholders to approve the Proposed Transaction as described in this Disclosure of Information.

V. EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

In accordance with the provisions of the applicable laws and regulations, the approval of this Proposed Transaction will be requested at the Company's EGMS which will be held on:

Day, Date : Wednesday, 14 December 2022
Time : 10:00 WIB - finished
Venue : Studio SCTV, SCTV Tower Floor 8, Senayan City,
Jl. Asia Afrika Lot. 19, Central Jakarta, 10270, Indonesia.

The EGMS agenda related to the Proposed Transaction is as follows:

First Agenda

Approval for the establishment of the Management and Employee Stock Ownership Program ("**MESOP Program**") with a maximum number of 35,000,000 shares or 0.2% of the issued and fully paid capital in the Company.

In connection with the First Agenda mentioned above, the Company will also propose to the EGMS to approve the granting of authority to the Board of Directors of the Company to take all necessary actions related to the decisions above, including but not limited to stating the resolutions of this EGMS in a separate deed before a Public Notary.

Further, The Company has announced the EGMS through (i) the eASY.KSEI website, (ii) the IDX website, and (iii) the Company's website (www.emc.id) on 7 November 2022.

Referring to Article 8A paragraphs (2) and (3) of POJK No. 14/2019, the requirements for attendance quorum and approval quorum which required for the MESOP Program are as follows:

1. The GMS may be held if the GMS is attended by more than 1/2 (one half) of the total shares with valid voting rights owned by independent shareholders and shareholders who are not affiliated with a public company, members of the Board of Directors, members of the Board of Commissioners, the controlling shareholder, or owner.
2. The resolution of the GMS as referred to in number 1 is valid if it is approved by more than 1/2 (one half) of the total shares with valid voting rights owned by independent shareholders and shareholders who are not affiliated with the public company, members of the Board of Directors, members of the Board of Commissioners, the controlling shareholder, or owner.
3. In the event that the quorum of the first GMS is not reached, the second GMS may be held if the GMS is attended by more than 1/2 (one half) of the total shares with valid voting rights owned by independent shareholders and shareholders who are not affiliated parties with a public company, members of the Board of Directors, members of the Board of Commissioners, the controlling shareholder, or owner.

4. The decision of the second GMS is valid if it is approved by more than 1/2 (one half) of the total shares with valid voting rights owned by independent shareholders and shareholders who are not affiliated with a public company, members of the Board of Directors, members of the Board of Commissioners, the controlling shareholder, or owner.
5. In the event that the quorum of attendance at the second GMS is not reached, the third GMS may be held provided that the third GMS is valid and has the right to make decisions if attended by independent shareholders and shareholders who are not affiliated with a public company, members of the Board of Directors, members of the Board of Commissioners, the controlling shareholder, or owner with valid voting rights, in a quorum of attendance determined by the OJK at the request of a public company.
6. The decision of the third GMS is valid if it is approved by independent shareholders and shareholders who are not affiliated with a public company, members of the Board of Directors, members of the Board of Commissioners, major shareholders, or controlling shareholders representing more than 50% (fifty percent) of the shares. owned by independent shareholders and shareholders who are not affiliated with a public company, members of the the Board of Directors, members of the Board of Commissioners, the controlling shareholder, or owner who are present at the GMS.
7. The holding of the GMS must be carried out in accordance with the provisions as stipulated in POJK No. 15/2020 and the Company's Articles of Association.

VI. ADDITIONAL INFORMATION

Any Shareholders who require further information in connection with this Disclosure of Information regarding the matters mentioned above may contact the Company on Working Days at the following address:

Headquarters:
Jl. Pulomas Barat VI No. 20, Kayu Putih, Pulo Gadung,
East Jakarta 13210, Indonesia.
Ph. (021) 2977 9977
Fax. (021) 2977 9977
Website: www.emc.id
Email: corsec@emc.id

Jakarta, 7 November 2022
PT Sarana Meditama Metropolitan Tbk
The Board of Directors